HomeHealthcare & Life SciencesPharmaceuticals Sarcoidosis Therapeutics Market

North America Sarcoidosis Therapeutics Market Size & Outlook, 2026-2034


North America Sarcoidosis Therapeutics Market Insights

  • As per Reed Intelligence insights, North America’s Sarcoidosis Therapeutics Market was valued at USD 564.3 Million in 2025 and is anticipated to expand to USD 1218.58 Million by 2034.
  • From 2026 to 2034, the market is anticipated to expand at a CAGR of 8.82%.
  • Within Drug Class, Corticosteroids accounted for the largest market size in 2025.
  • During the forecast period, Biologics is anticipated to remain the highest-growth segment within the Drug Class category.

Other Key Findings


  • The global Sarcoidosis Therapeutics Market size saw North America holding a share of 39.74% in 2025.
  • United States is forecasted to account for the leading share of the global market by 2034.
  • In North America, Canada is forecasted to be the fastest-expanding market, projected to reach USD 275.89 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 564.3 Million
Market Size In 2034 USD 1218.58 Million
Largest segment Corticosteroids
Units Revenue in USD Million
CAGR 8.82% (2026-2034)
Segmnetation Covered
North America
  1. United States
  2. Canada
Drug Class
  1. Corticosteroids
  2. Immunosuppressants
  3. Biologics
  4. Antimalarial Agents
Disease Type
  1. Pulmonary Sarcoidosis
  2. Cutaneous Sarcoidosis
  3. Cardiac Sarcoidosis
  4. Ocular Sarcoidosis
  5. Others
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports